Journal of Experimental Medicine

04/14/2026

Read our special collection of recent and exciting advances in , celebrating JEM’s long commitment to publishing outstanding basic as well as translational research.
👉 https://hubs.la/Q04bBpgJ0

04/10/2026

New JEM study from Mathew et al. of the Angeletti lab (https://hubs.la/Q04bmm1G0) shows that nasal tissue harbours T cells that ‘remember’ a pathogen long after infection is past. See Nature research highlight 👉 https://hubs.la/Q04bm1Ql0

Mathew et al. demonstrate that CD4 TRM form in the nasal tissue during influenza A virus infection. Influenza-specific CD4 TRM are predominantly Th17, depe

04/09/2026

Matthew R Hepworth, Richard K Grencis (The University of Manchester) discuss work by Forster et al (https://hubs.la/Q04bd4c00) reporting that Blimp-1 is a pivotal alarmin-activated transcription factor that is critical in controlling optimal effector cytokine secretion in ILC2 cells during type 2 immunity. https://hubs.la/Q04bd6QF0

04/08/2026

Our April issue is here! https://hubs.la/Q049W6TJ0
The cover depicts a confocal image of colonic myenteric plexus from tamoxifen- and DSS-treated NesER-CreR26-STOPf/ftdTomato (Cre+) mice at week 10 afer starting DSS. From Kurapati and Shin et al. (https://hubs.la/Q049V_g00)

04/06/2026

CD4 tissue resident memory cells are established and persist in the upper airways after infection and protect from re-infection with drifted strains. New study by Nimitha Mathew, Davide Angeletti and colleagues (University of Gothenburg): https://hubs.la/Q049HYP60

04/02/2026

Shaima Salman, Alexander D. MacKerell, Gregg L. Semenza et al. develop the first dual HIF-1/2 inhibitors that bind to the most highly conserved domains of both proteins, show activity against a range of cancers, are orally bioavailable, & markedly improve responses to immune checkpoint blockade in mouse tumor models. https://hubs.la/Q049rWjN0

See the accompanying press release: https://hubs.la/Q049rYj70

04/02/2026

📰 : Researchers at Johns Hopkins Medicine and University of Maryland School of Pharmacy have developed a set of novel, first-in-class drugs that inhibit hypoxia-inducible factors 1 and 2, a pair of transcription factors considered to be “master regulators” of cancer progression 👉 https://hubs.la/Q049gfRy0

The study, published today in the Journal of Experimental Medicine (JEM), (https://hubs.la/Q049glrs0) shows that these drugs, when combined with immunotherapy, can completely eliminate breast, colorectal, melanoma, and prostate tumors in mice, suggesting that they could eventually be used to treat a broad range of cancers in humans.

03/31/2026

Kieran R. Adam, Aamir Suhail, Vijay K. Kuchroo (Harvard Medical School), and Dario A.A. Vignali (Pitt School of Medicine) highlight the challenges and novel approaches to developing agonistic inhibitory receptor (IR)-targeted therapies to treat and inflammatory disorders.
https://hubs.la/Q0493WnZ0

03/31/2026

Patrycja M. Forster, Christoph S.N. Klose and colleagues (Charité - Universitätsmedizin Berlin) identify the transcriptional network controlling effector functions of ILC2s downstream of the IL-33 receptor: the Blimp-1–IRF4 axis regulates IL-5 and IL-13 production, driving either worm expulsion or during allergic lung inflammation https://hubs.la/Q0493y0x0

03/27/2026

New study from Jiaxi Song, Dan Cui, Fengyin Li and colleagues (University of Science and Technology of China) reveals that Mettl8 maintains stem-like TPEX cells by stabilizing Tcf1 via m³C modification and facilitating chromatin looping at the Tox locus. https://hubs.la/Q048Fbw20

03/27/2026

Lun Li, Mark Kahn et al. (Perelman School of Medicine at the University of Pennsylvania) show that the TIE2 receptor links MEKK3–KLF2/4 and PI3K signaling during cerebral cavernous malformation (CCM) formation, identifying TIE2 inhibition as a potential treatment strategy for CCM disease. https://hubs.la/Q048F0NK0

03/27/2026

📰 : Researchers at Perelman School of Medicine at the University of Pennsylvania have identified a cell surface receptor protein called TIE2 as the missing link between two key signaling pathways that drive the growth of blood vessel abnormalities known as cerebral cavernous malformations (CCMs). The study, published today in JEM (https://hubs.ly/Q048Cf260), suggests that drugs targeting TIE2 could be used to prevent the formation of CCMs, which, if left untreated, can cause brain hemorrhages, strokes, and seizures. https://hubs.ly/Q048CfBP0